000 | 05700nam a22005415i 4500 | ||
---|---|---|---|
001 | 978-3-319-90603-4 | ||
003 | DE-He213 | ||
005 | 20210201191408.0 | ||
007 | cr nn 008mamaa | ||
008 | 180620s2018 gw | s |||| 0|eng d | ||
020 |
_a9783319906034 _9978-3-319-90603-4 |
||
050 | 4 | _aRS380 | |
050 | 4 | _aRS190-210 | |
072 | 7 |
_aTDCW _2bicssc |
|
072 | 7 |
_aMED072000 _2bisacsh |
|
072 | 7 |
_aTDC _2thema |
|
082 | 0 | 4 |
_a615.19 _223 |
245 | 1 | 0 |
_aChallenges in Protein Product Development _h[electronic resource] / _cedited by Nicholas W. Warne, Hanns-Christian Mahler. |
250 | _a1st ed. 2018. | ||
264 | 1 |
_aCham : _bSpringer International Publishing : _bImprint: Springer, _c2018. |
|
300 |
_aXVI, 599 p. 130 illus., 75 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_atext file _bPDF _2rda |
||
490 | 1 |
_aAAPS Advances in the Pharmaceutical Sciences Series, _x2210-7371 ; _v38 |
|
500 | _aAcceso multiusuario | ||
505 | 0 | _aPart 1. Formulation Development of Biologics -- Introduction into Formulation Development of Biologics -- Part 2. Challenges with Excipients -- Polysorbate Degradation and Quality -- Sucrose and Trehalose in Therapeutic Protein Formulations -- Part 3. High Concentration Proteins -- Introduction to High-Concentration Proteins -- Solubility, Opalescence & Particulate Matter -- Analytical Characterization and Predictive Tools for Highly Concentrated Protein Formulations -- Practical Considerations for High Concentration Protein Formulations -- Part 4. Container-Closure Systems -- Parenteral Container Closure Systems -- Development of Prefilled Syringe Combination Products for Biologics -- Special Topics in Analytics of Pre-filled Syringes -- C Mini-Pumps -- Container Closure Integrity Testing of Primary Containers for Parenteral Products -- Chemical Durability of Glass - Delamination -- Part 5. Processing Considerations -- Bulk Protein Solution: Freeze Thaw Process, Storage and Shipping Considerations -- Leachables and Extractables: From Regulatory Expectations to Laboratory Assessment -- Biotherapeutic Drug Product Manufacturing and Process Development -- Line Sterilization Considerations and VHP -- Lyophilization: Process Design, Robustness and Risk Management -- Fogging -- Scientific Approaches for the Application of QbD Principles in Lyophilization Process Development -- Manufacturing of Highly Potent Drug Product in a Clinical Multi-Product Aseptic Facility and Transfer of Principles to Antibiotic Drug Product -- Part 6. Novel Constructs -- Introduction into Novel Constructs -- Novel Constructs - Half-Life Extensions -- Fc Fusion Proteins -- Part 7. Lifecycle Management -- Lifecycle Management of Biotherapeutic Dosage Forms -- Switching from an IV to an SC Formulation - Considerations for Formulation Development and Formulation Bridging. | |
520 | _aIn this volume, the authors discuss the many significant challenges currently faced in biotechnology dosage form development, providing guidance, shared experience and thoughtful reflection on how best to address these potential concerns. As the field of therapeutic recombinant therapeutic proteins enters its fourth decade and the market for biopharmaceuticals becomes increasingly competitive, companies are increasingly dedicating resources to develop innovative biopharmaceuticals to address unmet medical needs. Often, the pharmaceutical development scientist is encountering challenging pharmaceutical properties of a given protein or by the demands placed on the product by stability, manufacturing and preclinical or clinical expectations, as well as the evolving regulatory expectations and landscape. Further, there have been new findings that require close assessment, as for example those related to excipient quality, processing, viscosity and device compatibility and administration, solubility and opalescence and container-closure selection. The literature varies widely in its discussion of these critical elements and consensus does not exist. This topic is receiving a great deal of attention within the biotechnology industry as well as with academic researchers and regulatory agencies globally. Therefore, this book is of interest for business leaders, researchers, formulation and process development scientists, analytical scientists, QA and QC officers, regulatory staff, manufacturing leaders and regulators active in the pharmaceutical and biotech industry, and expert reviewers in regulatory agencies. | ||
541 |
_fUABC ; _cTemporal ; _d01/01/2021-12/31/2023. |
||
650 | 0 | _aPharmaceutical technology. | |
650 | 1 | 4 |
_aPharmaceutical Sciences/Technology. _0https://scigraph.springernature.com/ontologies/product-market-codes/B21010 |
700 | 1 |
_aWarne, Nicholas W. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
700 | 1 |
_aMahler, Hanns-Christian. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
710 | 2 | _aSpringerLink (Online service) | |
773 | 0 | _tSpringer Nature eBook | |
776 | 0 | 8 |
_iPrinted edition: _z9783319906010 |
776 | 0 | 8 |
_iPrinted edition: _z9783319906027 |
776 | 0 | 8 |
_iPrinted edition: _z9783030080525 |
830 | 0 |
_aAAPS Advances in the Pharmaceutical Sciences Series, _x2210-7371 ; _v38 |
|
856 | 4 | 0 |
_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=https://doi.org/10.1007/978-3-319-90603-4 |
912 | _aZDB-2-SBL | ||
912 | _aZDB-2-SXB | ||
942 | _cLIBRO_ELEC | ||
999 |
_c242992 _d242991 |